We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Assessing Portal Hypertension With Methacetin Breath Test

This study is currently recruiting participants.
Verified August 2017 by Exalenz Bioscience LTD.
ClinicalTrials.gov Identifier:
First Posted: May 21, 2014
Last Update Posted: August 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Exalenz Bioscience LTD.
This study will be used to train an algorithm using Methacetin breath test (MBT) measures and to select a cut-off to determine presence or absence of Clinically Significant Portal Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg

Condition Intervention
Patients With Compensated Liver Cirrhosis Device: Methacetin Breath Test

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis

Resource links provided by NLM:

Further study details as provided by Exalenz Bioscience LTD.:

Primary Outcome Measures:
  • CSPH [ Time Frame: 1 hour ]
    Clinically significant portal hypertension , defined as Hepatic Venous Pressure Gradient (HVPG)>=10mmHg

Secondary Outcome Measures:
  • HVPG>=12 [ Time Frame: 1 hour ]
    Hepatic Venous Pressure Gradient greater than 12 is an indicator of bleeding varices

Estimated Enrollment: 200
Actual Study Start Date: November 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Compensated cirrhotic patients
A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
Device: Methacetin Breath Test
13C labelled methacetin solution for breath test monitoring


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult men or women (>18 years of age)
  • Known chronic liver disease with cirrhosis
  • Europe: Indicated to undergo HVPG testing
  • US: Consented for HVPG
  • For patients treated with beta blockers: They have to be on a stable dose for at least 6 weeks prior to any study related tasks
  • For patients who stopped their treatment with beta blockers: Their last dose should be at least 6 weeks prior to any study related tasks

Exclusion Criteria:

  • Decompensated cirrhosis as clinically defined by the presence of ascites, hepatic encephalopathy, variceal bleeding or hepatorenal syndrome
  • Renal failure (creatinine > 2.5 mg/dl)
  • Known acute renal tubular disease Known hypotension (Systolic Pressure <100mmHg)
  • Hypocoagulablity defined as PT >6 and INR >2.3.
  • Congestive heart failure (assessed clinically as NIHA >2)
  • Known pulmonary hypertension (right ventricular systolic pressure > 45 mm Hg)
  • Uncontrolled diabetes mellitus (HBA1C >9.5gr%)
  • Concurrent prednisone or immunosuppressive treatment, if therapy and/or response to treatment are not stable for at least 3 months.
  • Documented or suspected hepatocellular carcinoma
  • Gastric bypass surgery or extensive small bowel resection
  • Total parenteral nutrition
  • Any organ transplant recipient
  • Pregnant or breast feeding
  • Allergy to acetaminophen and/or other related medications
  • Documented drug-related concurrent hepatotoxicity or drug-related silent steatosis or drug-related fibrosis (e.g. amiodarone, methotrexate and tamoxifen)
  • Uncontrolled malabsorption or diarrhea
  • Documented non-cirrhotic PHT, partial / complete portal venous occlusion, hepatic venous occlusion, previous PHT surgery, or placement of a transjugular intrahepatic portosystemic shunt (TIPS)
  • Primary or secondary biliary cirrhosis, primary or secondary sclerosing cholangitis, hepatic sarcoidosis, or other cholestatic disorders
  • Subjects unable to perform the MBT within 7 days of HVPG procedure.
  • Subject should not have taken any of the following for at least 48 hours prior to the breath test: Acyclovir , allopurinol, amiodarone, carbamazepine, cimetidine, ciprofloxacin, daidzein, (herbal) disulfiram, echinacea, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine, phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil, zileuton or oral contraceptives or any medication that might interfere with Methacetin metabolism or might affect CYP 1A2
  • Subject should not have taken amiodarone or statins within the last 30 days prior to the breath test or HVPG procedure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02143778

Contact: Avraham Hershkowitz, MSc +972-8-9737513 avrahamh@exalenz.com

United States, Connecticut
VA Connecticut HealthCare System Recruiting
New Haven, Connecticut, United States, 06516
Contact: Jessica Jordan    203-932-5711 ext 2206    jessica.jordan@yale.edu   
Principal Investigator: Guadalupe Garcia-Tsao, M.D.         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Christopher Kigongo    919-668-6579    Christopher.kigongo@duke.edu   
Principal Investigator: Manal AbdelMalek, MD         
United States, Virginia
Virginia Commonwealth University Not yet recruiting
Richmond, Virginia, United States, 23298
Contact: Stephanie Taylor    804-828-9311    stephanie.taylor@vcuhealth.org   
Principal Investigator: Velimir Luketic, MD         
Hôpital Beaujon Recruiting
Clichy (Paris), France
Contact: Ouardia NEKACHTALI    +33 1 40 87 54 31    ouardia_n@yahoo.fr   
Principal Investigator: Pierre E Rautou, M.D.         
Hopital Purpan Recruiting
Toulouse, France
Contact: Carine Barret    + 33 5 61 77 99 06    barret.c@chu-toulouse.fr   
Principal Investigator: Christophe Bureau, M.D.         
(University of Barcelona) Hospital Clinic Recruiting
Barcelona, Spain
Contact: Rosa Sáez Carceller    34 93 2275400    RMSAEZ@clinic.ub.es   
Principal Investigator: Juan Carlos Garcia Pagan, MD         
Hospital Universitario Ramón y Cajal Recruiting
Madrid, Spain
Contact: Cristina M Martin    +34 913368592    mcrismartin@terra.com   
Principal Investigator: Agustin Albillos, M.D.         
Inselspital Recruiting
Bern, Switzerland, 3010
Contact: Kathrin Husi    +41 31 632 59 33    kathrin.husi@insel.ch   
Principal Investigator: Annalisa Berzigotti, M.D.         
Sponsors and Collaborators
Exalenz Bioscience LTD.
Principal Investigator: Juan Carlos Garcia Pagan, MD University Hospital Barcelona
  More Information

Responsible Party: Exalenz Bioscience LTD.
ClinicalTrials.gov Identifier: NCT02143778     History of Changes
Other Study ID Numbers: CSPH-EX-4014
2014-002037-59 ( EudraCT Number )
First Submitted: May 18, 2014
First Posted: May 21, 2014
Last Update Posted: August 17, 2017
Last Verified: August 2017

Keywords provided by Exalenz Bioscience LTD.:

Additional relevant MeSH terms:
Liver Cirrhosis
Hypertension, Portal
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Liver Diseases
Digestive System Diseases